24–25 Nov 2026
IARC
Europe/Paris timezone

Premature mortality and associated productivity losses due to Epstein-Barr virus: a global analysis

T1-5
24 Nov 2026, 10:45
10m
RC 150 - Auditorium (IARC)

RC 150 - Auditorium

IARC

25 avenue Tony Garnier, Lyon, France
Short oral Cancer Etiology, Epidemiology & Risk Factors Cancer Etiology, Epidemiology & Risk Factors

Speaker

Yue Huang (International Agency for Research on Cancer)

Description

Background: Emerging aetiological evidence has broadened the spectrum of diseases attributable to Epstein–Barr virus (EBV). Quantifying productivity losses from EBV-associated premature mortality can inform investment in research and prevention.
Methods: We estimated productivity losses from premature mortality attributable to EBV across seven diseases in 185 countries and territories in 2024: Burkitt lymphoma, diffuse large B-cell lymphoma, extranodal NK/T-cell lymphoma of nasal type, Hodgkin lymphoma, nasopharyngeal carcinoma (NPC), gastric cancer, and multiple sclerosis (MS). Years of productive life lost (YPLL) were calculated using GLOBOCAN 2024, Cancer Incidence in Five Continents, Global Burden of Disease Study 2023, and WHO life tables, defining premature deaths as those occurring before age 65. EBV population attributable fractions were primarily obtained from published studies. Paid and unpaid productivity losses were valued using human capital and opportunity cost approaches, respectively, with economic, labour, and unpaid activity data from international databases.
Results: In 2024, an estimated 68,854 premature deaths were attributable to EBV, resulting in approximately 0.9 million YPLL. Total productivity losses amounted to US$13.8 billion, equivalent to 0.013% of global GDP. MS (US$4.8 billion) and NPC (US$4.3 billion) were the largest contributors. MS predominated in Europe, North America, and Australia/New Zealand, whereas NPC contributed substantially in Eastern and South-Eastern Asia. Losses were approximately twice as high in males as in females.
Conclusions: EBV-associated premature mortality imposes substantial societal costs through lost paid and unpaid productivity. These findings support greater investment in EBV research, prevention, and control, with priorities informed by regional differences in the contributions of individual diseases.

Authors

Yue Huang (International Agency for Research on Cancer) Dr Yek-Ching Kong (International Agency for Research on Cancer) Dr Mayo Hirabayashi (Imperial College London) Harriet Rumgay (International Agency for Research on Cancer) Isabelle Soerjomataram (International Agency for Research on Cancer) Gary Clifford (International Agency for Research on Cancer; Shanxi Medical University)

Presentation materials

There are no materials yet.